Biohaven (BHVN) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Septerna (SEPN) has outperformed Biohaven (BHVN) over the past year, gaining 65.8% versus a loss of 29.9%. Biohaven is the larger company by market cap ($1.82 billion vs $1.79 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | SEPN |
|---|---|---|
| Share price | $12.08 | $38.37 |
| Market cap | $1.82B | $1.79B |
| 1-day change | +1.26% | +3.98% |
| YTD return | +7.00% | +37.63% |
| 1-year return | -29.89% | +65.82% |
| EPS (TTM) | $-4.62 | $-0.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $45.95M |
| Revenue growth (YoY) | — | +4174.51% |
| Net income (latest FY) | $-738.82M | $-48.88M |
| Operating margin | — | -148.63% |
| Net margin | — | -106.37% |
| 52-week high | $18.57 | $51.10 |
| 52-week low | $7.48 | $17.55 |
| Distance from 52-week high | -34.93% | -24.91% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +41.31% |
| Average volume | 2.63M | 390.66K |
| Shares outstanding | 151.04M | 46.68M |
| Employees | 274 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed BHVN by 95.7 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
BHVN vs SEPN FAQ
Which is bigger, Biohaven or Septerna?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.79B for Septerna (SEPN).
Which stock has performed better over the past year, BHVN or SEPN?
SEPN returned +65.82% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.